UK investments in global infectious disease research 1997–2010: a case study

Head, Michael G; Fitchett, Joseph R; Cooke, Mary; Wurie, Fatima; Hayward, Andrew; Atun, Rifat

doi:10.1016/s1473-3099(12)70261-x

Cited by 111 publications

(107 citation statements)

References 21 publications

Supporting

Mentioning

106

Contrasting

Order By: Relevance

“…This is an unexpected finding, given that across all infectious diseases 35.6% of funding had a clear global health component 8. The lower investment may be a result of almost all of the research being preclinical, and thus hard to attribute to a global health category (most of the global health research in the larger study is translational in nature).…”

Section: Discussionmentioning

confidence: 98%

Systematic analysis of funding awarded for mycology research to institutions in the UK, 1997–2010

et al. 2014

Self Cite

View full text Add to dashboard Cite

ObjectivesFungal infections cause significant global morbidity and mortality. We have previously described the UK investments in global infectious disease research, and here our objective is to describe the investments awarded to UK institutions for mycology research and outline potential funding gaps in the UK portfolio.DesignSystematic analysis.SettingUK institutions carrying out infectious disease research.Primary and secondary outcome measuresPrimary outcome is the amount of funding and number of studies related to mycology research. Secondary outcomes are describing the investments made to specific fungal pathogens and diseases, and also the type of science along the R&D value chain.MethodsWe systematically searched databases and websites for information on research studies from public and philanthropic funding institutions awarded between 1997 and 2010, and highlighted the mycology-related projects.ResultsOf 6165 funded studies, we identified 171 studies related to mycology (total investment £48.4 million, 1.9% of all infection research, with mean annual funding £3.5 million). Studies related to global health represented 5.1% of this funding (£2.4 million, compared with 35.6% of all infectious diseases). Leading funders were the Biotechnology and Biological Sciences Research Council (£14.8 million, 30.5%) and Wellcome Trust (£12.0 million, 24.7%). Preclinical studies received £42.2 million (87.3%), with clinical trials, intervention studies and implementation research in total receiving £6.2 million (12.7%). By institution, University of Aberdeen received most funding (£16.9 million, 35%). Studies investigating antifungal resistance received £1.5 million (3.2%).ConclusionsThere is little translation of preclinical research into clinical trials or implementation research in spite of substantial disease burden globally, and there are few UK institutions that carry out significant quantities of mycology research of any type. In the context of global health and the burden of disease in low-income countries, more investment is required for mycology research.

show abstract

Section: Discussionmentioning

confidence: 98%

Systematic analysis of funding awarded for mycology research to institutions in the UK, 1997–2010

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…And without any benefit such therapies contribute to a number of adverse consequences, including development of bacterial resistance 8 and increased hospital cost for treating resistant microbes. A cross sectional study was conducted to compare antibiotic prescribing for inpatients, in two private sector tertiary care hospitals in Ujjain; which also showed an inappropriate use of antibiotics.…”

Section: Disease Of the Nose: Sinus Infectionmentioning

confidence: 99%

Untitled

2016

IJPSR

View full text Add to dashboard Cite

show abstract

“…Infectious diseases account for 15 million deaths per year globally, equivalent to a 43% global burden of disease [1]. Until recently, the management of these diseases has been made easier by antibiotics [2,3].…”

Section: Introductionmentioning

confidence: 99%

Surveillance of antibiotic use in the private sector in Namibia using sales and claims data

Pereko

Lubbe

Essack

2016

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Antibiotics are among the most commonly used therapeutic agents for humans globally, and their use has been associated with the development of resistance. The objective of this study was to identify sources for quantifying antibiotic usage patterns and to assess such use in ambulatory patients in the private health sector of Namibia. Methodology: A retrospective analysis of prescription claims data and sales data for the period 2008 to 2011 was conducted. Antibiotic use was expressed in the number of antibiotic-containing prescriptions and volume of units sold and then standardized using defined daily dose per 1,000 inhabitants per day. Results: Antibiotic usage was highest in females (53%), in people 18-45 years of age (41%), and in Windhoek (34%). Overall, wholesale data showed higher antibiotic use than prescription claims data. However, both sources showed similar patterns of antibiotic use. Penicillins were the most used pharmacological group, with amoxicillin/clavulanic acid combination being the most used of the agents. Conclusion: Antibiotic use in the private sector of Namibia is comparable to that of high-consuming European countries such as Italy. A trend observed in this study was the decrease in the use of narrow-spectrum antibiotics in favour of broad-spectrum and newer antibiotics. Since this was the first study to assess antibiotic use in the private sector of Namibia, it could serve as a starting point for continued monitoring of antibiotic use in the whole of Namibia in the context of the World Health Organization's Global Action Plan to contain antibiotic resistance.

show abstract

UK investments in global infectious disease research 1997–2010: a case study

Abstract: None.

Cited by 111 publications

References 21 publications

Systematic analysis of funding awarded for mycology research to institutions in the UK, 1997–2010

Systematic analysis of funding awarded for mycology research to institutions in the UK, 1997–2010

Untitled

Surveillance of antibiotic use in the private sector in Namibia using sales and claims data

Contact Info

Product

Resources

About